The Experts below are selected from a list of 324 Experts worldwide ranked by ideXlab platform
Marcus Maurer - One of the best experts on this subject based on the ideXlab platform.
-
benefit from reslizumab treatment in a patient with chronic spontaneous Urticaria and cold Urticaria
Journal of The European Academy of Dermatology and Venereology, 2018Co-Authors: Marcus Maurer, Sabine Altrichter, Martin Metz, Torsten Zuberbier, Martin K Church, Karl Christian BergmannAbstract:Chronic Urticaria (CU) is a group of common and debilitating conditions containing both chronic spontaneous Urticaria (CSU) and chronic inducible Urticarias (CIndU) including cold Urticaria (ColdU) [1]. While antihistamines and omalizumab are effective treatments for both CSU and ColdU [2], many patients show insufficient response to either or both of these treatments [3], and additional and better therapies are needed [4]. This article is protected by copyright. All rights reserved.
-
omalizumab treatment in patients with chronic inducible Urticaria a systematic review of published evidence
The Journal of Allergy and Clinical Immunology, 2017Co-Authors: Marcus Maurer, Martin Metz, Randolf Brehler, Uwe Hillen, Thilo Jakob, Vera Mahler, Claudia Pfohler, Petra Staubach, Regina Treudler, Bettina WediAbstract:Background Omalizumab, a recombinant anti-IgE antibody, effectively treats chronic spontaneous Urticaria. Evidence is lacking in patients with chronic inducible Urticarias (CIndUs), which are frequently H 1 -antihistamine resistant. Objective From the current published literature, we aimed to determine the strength of evidence for omalizumab efficacy and safety in the treatment of CIndUs. Methods We performed a PubMed search to identify evidence on omalizumab use in the following 9 CIndU subtypes: symptomatic dermographism, cold Urticaria, delayed-pressure Urticaria, solar Urticaria, heat Urticaria, vibratory angioedema, cholinergic Urticaria, contact Urticaria, and aquagenic Urticaria. Results Forty-three trials, case studies, case reports, and analyses were identified. Our review indicates that omalizumab has substantial benefits in patients with various CIndUs. The evidence is strongest for symptomatic dermographism, cold Urticaria, and solar Urticaria. Little/no evidence was available on vibratory angioedema and aquagenic and contact Urticaria. Our review supports rapid onset of action demonstrated through early symptom control in most cases, sometimes within 24 hours. Many patients gained complete/partial symptom relief and substantially improved quality of life. Adverse events were generally low, with omalizumab being well tolerated by most patients, including children. Conclusions A strong body of evidence supports the use of omalizumab in the treatment of patients with therapy-refractory CIndU. More data from randomized controlled studies are warranted.
-
the definition and diagnostic testing of physical and cholinergic Urticarias eaaci ga2len edf unev consensus panel recommendations
Allergy, 2009Co-Authors: Markus Magerl, Martin Metz, Elena Borzova, A Gimenezarnau, F Lawlor, P Mathelierfusade, C E H Grattan, A Mlynek, Marcus MaurerAbstract:The recommendations for the definition and diagnosis presented in this position paper are the result of a panel consensus meeting held in December 2008 in Berlin. This consensus meeting was a joint initiative of EAACI (European Academy of Allergology and Clinical Immunology) Dermatology Section, the EU-funded network of excellence, GA2LEN (Global Allergy and Asthma European Network), the EDF (European Dermatology Forum) and UNEV (Urticaria network e.V.). The aim of these recommendations is to improve the diagnosis and management of patients with physical Urticaria or cholinergic Urticaria and to promote research and a better understanding of these diseases. Our recommendations used the paper produced by a 1996 expert meeting (1) and they acknowledge the latest changes in our understanding of physical Urticarias and cholinergic Urticaria as well as the recent development of novel diagnostic tools. In addition, this consensus paper highlights areas of need for further research.
-
Urticaria current opinions about etiology diagnosis and therapy
Acta Dermato-venereologica, 2007Co-Authors: Torsten Zuberbier, Marcus MaurerAbstract:In the last few decades an increasing understanding of the pathomechanisms involved in Urticaria has highlighted the heterogeneity of different subtypes. According to the new European Academy of Allergology and Clinical Immunology/Global Allergy and Asthma European Network/European Dermatology Forum (EAACI/GA(2)LEN/ EDF) guidelines, Urticaria subtypes can be grouped into spontaneous Urticaria, which includes acute Urticaria and chronic Urticaria, the physical Urticarias, and other Urticaria disorders, including, for example, contact Urticaria. Clarity of nomenclature is required not only to choose the correct measures in diagnosis and management, but also to compare data from different studies. Urticaria has a profound impact on quality of life and performance. Effective treatment is thus required in all cases where avoidance of eliciting factors is not feasible. For symptomatic relief, non-sedating H1-antihistamines are the first choice in most subtypes of Urticaria; however, double-blind controlled studies have shown that the dosages required may exceed those recommended for other diseases, e.g. allergic rhinitis. The current guidelines therefore suggest increasing the dosage up to four-fold, whereas alternative treatments should be reserved as add-on therapy for unresponsive patients.
-
eaaci ga2len edf guideline management of Urticaria
Allergy, 2006Co-Authors: Torsten Zuberbier, M W Greaves, Marcus Maurer, C E H Grattan, Carsten Bindslevjensen, Walter Canonica, Beate M Henz, Alexander Kapp, M M Kozel, Hans F MerkAbstract:This guideline is the result of a consensus reached during a panel discussion at the second International Consensus Meeting on Urticara, Urticaria 2004, a joint initiative of the EAACI Dermatology Section and GA2LEN. Urticaria has a profound impact on the quality of life, and effective treatment is therefore required. The recommended first line treatment are nonsedating H1 antihistamines. They have proven to be effective in double-blind controlled studies, but dosages increased up to fourfold over the recommended doses may be necessary. However, for different Urticaria subtypes and in view of individual variation in the course of the disease and response to treatment, additional or alternative therapies may be required. Immunosuppressive drugs like cyclosporin A and corticosteroids are not recommended for long-term treatment due to unavoidable severe adverse effects. This guideline was, in addition, accepted by the European Dermatology Forum (EDF) and formally approved by the European Union of Medical Specialists (UEMS).
Martin Metz - One of the best experts on this subject based on the ideXlab platform.
-
benefit from reslizumab treatment in a patient with chronic spontaneous Urticaria and cold Urticaria
Journal of The European Academy of Dermatology and Venereology, 2018Co-Authors: Marcus Maurer, Sabine Altrichter, Martin Metz, Torsten Zuberbier, Martin K Church, Karl Christian BergmannAbstract:Chronic Urticaria (CU) is a group of common and debilitating conditions containing both chronic spontaneous Urticaria (CSU) and chronic inducible Urticarias (CIndU) including cold Urticaria (ColdU) [1]. While antihistamines and omalizumab are effective treatments for both CSU and ColdU [2], many patients show insufficient response to either or both of these treatments [3], and additional and better therapies are needed [4]. This article is protected by copyright. All rights reserved.
-
omalizumab treatment in patients with chronic inducible Urticaria a systematic review of published evidence
The Journal of Allergy and Clinical Immunology, 2017Co-Authors: Marcus Maurer, Martin Metz, Randolf Brehler, Uwe Hillen, Thilo Jakob, Vera Mahler, Claudia Pfohler, Petra Staubach, Regina Treudler, Bettina WediAbstract:Background Omalizumab, a recombinant anti-IgE antibody, effectively treats chronic spontaneous Urticaria. Evidence is lacking in patients with chronic inducible Urticarias (CIndUs), which are frequently H 1 -antihistamine resistant. Objective From the current published literature, we aimed to determine the strength of evidence for omalizumab efficacy and safety in the treatment of CIndUs. Methods We performed a PubMed search to identify evidence on omalizumab use in the following 9 CIndU subtypes: symptomatic dermographism, cold Urticaria, delayed-pressure Urticaria, solar Urticaria, heat Urticaria, vibratory angioedema, cholinergic Urticaria, contact Urticaria, and aquagenic Urticaria. Results Forty-three trials, case studies, case reports, and analyses were identified. Our review indicates that omalizumab has substantial benefits in patients with various CIndUs. The evidence is strongest for symptomatic dermographism, cold Urticaria, and solar Urticaria. Little/no evidence was available on vibratory angioedema and aquagenic and contact Urticaria. Our review supports rapid onset of action demonstrated through early symptom control in most cases, sometimes within 24 hours. Many patients gained complete/partial symptom relief and substantially improved quality of life. Adverse events were generally low, with omalizumab being well tolerated by most patients, including children. Conclusions A strong body of evidence supports the use of omalizumab in the treatment of patients with therapy-refractory CIndU. More data from randomized controlled studies are warranted.
-
the definition diagnostic testing and management of chronic inducible Urticarias the eaaci ga2len edf unev consensus recommendations 2016 update and revision
Allergy, 2016Co-Authors: Markus Magerl, Sabine Altrichter, Torsten Zuberbier, Elena Borzova, A Gimenezarnau, Clive Grattan, F Lawlor, P Mathelierfusade, Raisa Meshkova, Martin MetzAbstract:These recommendations for the definition, diagnosis and management of chronic inducible Urticaria (CIndU) extend, revise and update our previous consensus report on physical Urticarias and cholinergic Urticaria (Allergy, 2009). The aim of these recommendations is to improve the diagnosis and management of patients with CIndU. Our recommendations acknowledge the latest changes in our understanding of CIndU, and the available therapeutic options, as well as the development of novel diagnostic tools.
-
anti immunoglobulin e treatment of patients with recalcitrant physical Urticaria
International Archives of Allergy and Immunology, 2011Co-Authors: Martin Metz, Erika Ardelean, Frank Siebenhaar, K. Weller, Birgit Kessler, Karoline Krause, Sabine Altrichter, Markus Magerl, Torsten ZuberbierAbstract:In physical Urticaria, exogenous physical factors such as thermal triggers, solar radiation and mechanic triggers including friction or pressure are responsible for the elicitation of symptoms in the skin of patients. Avoidance of the respective stimulus is usually difficult or impossible, and many patients are not sufficiently treated with standard antihistamines. We report that treatment with omalizumab (Xolair®) of 7 patients with physical Urticarias [solar Urticaria (n = 2), Urticaria factitia/symptomatic dermographism (n = 2), cold Urticaria, delayed pressure Urticaria and localized heat Urticaria] resulted in complete symptom control within days after the first injection in 5 patients. In 1 patient, symptoms improved after increasing the dose of omalizumab, and 1 patient with localized heat Urticaria did not respond significantly to treatment. Before anti-immunoglobulin E treatment, all patients had suffered from their physical Urticaria for years and had had numerous unsuccessful therapies. The overall excellent responses to omalizumab treatment reported here indicate that anti-immunoglobulin E is a safe and effective treatment for recalcitrant physical Urticarias.
-
the definition and diagnostic testing of physical and cholinergic Urticarias eaaci ga2len edf unev consensus panel recommendations
Allergy, 2009Co-Authors: Markus Magerl, Martin Metz, Elena Borzova, A Gimenezarnau, F Lawlor, P Mathelierfusade, C E H Grattan, A Mlynek, Marcus MaurerAbstract:The recommendations for the definition and diagnosis presented in this position paper are the result of a panel consensus meeting held in December 2008 in Berlin. This consensus meeting was a joint initiative of EAACI (European Academy of Allergology and Clinical Immunology) Dermatology Section, the EU-funded network of excellence, GA2LEN (Global Allergy and Asthma European Network), the EDF (European Dermatology Forum) and UNEV (Urticaria network e.V.). The aim of these recommendations is to improve the diagnosis and management of patients with physical Urticaria or cholinergic Urticaria and to promote research and a better understanding of these diseases. Our recommendations used the paper produced by a 1996 expert meeting (1) and they acknowledge the latest changes in our understanding of physical Urticarias and cholinergic Urticaria as well as the recent development of novel diagnostic tools. In addition, this consensus paper highlights areas of need for further research.
Torsten Zuberbier - One of the best experts on this subject based on the ideXlab platform.
-
benefit from reslizumab treatment in a patient with chronic spontaneous Urticaria and cold Urticaria
Journal of The European Academy of Dermatology and Venereology, 2018Co-Authors: Marcus Maurer, Sabine Altrichter, Martin Metz, Torsten Zuberbier, Martin K Church, Karl Christian BergmannAbstract:Chronic Urticaria (CU) is a group of common and debilitating conditions containing both chronic spontaneous Urticaria (CSU) and chronic inducible Urticarias (CIndU) including cold Urticaria (ColdU) [1]. While antihistamines and omalizumab are effective treatments for both CSU and ColdU [2], many patients show insufficient response to either or both of these treatments [3], and additional and better therapies are needed [4]. This article is protected by copyright. All rights reserved.
-
the definition diagnostic testing and management of chronic inducible Urticarias the eaaci ga2len edf unev consensus recommendations 2016 update and revision
Allergy, 2016Co-Authors: Markus Magerl, Sabine Altrichter, Torsten Zuberbier, Elena Borzova, A Gimenezarnau, Clive Grattan, F Lawlor, P Mathelierfusade, Raisa Meshkova, Martin MetzAbstract:These recommendations for the definition, diagnosis and management of chronic inducible Urticaria (CIndU) extend, revise and update our previous consensus report on physical Urticarias and cholinergic Urticaria (Allergy, 2009). The aim of these recommendations is to improve the diagnosis and management of patients with CIndU. Our recommendations acknowledge the latest changes in our understanding of CIndU, and the available therapeutic options, as well as the development of novel diagnostic tools.
-
physical Urticarias and cholinergic Urticaria
Immunology and Allergy Clinics of North America, 2014Co-Authors: Marina Abajian, Sabine Altrichter, N Schoepke, Torsten ZuberbierAbstract:: Physical Urticarias are a unique subgroup of chronic Urticaria in which Urticarial responses can be reproducibly induced by different specific physical stimuli acting on the skin. These conditions include Urticaria factitia/symptomatic dermographism, delayed pressure Urticaria, cold contact Urticaria, heat contact Urticaria, solar Urticaria, and vibratory Urticaria/angioedema. Physical Urticarias and cholinergic Urticarias are diagnosed based on the patients' history and provocation tests including trigger threshold testing where possible. Treatment is mainly symptomatic. Many patients benefit from avoiding eliciting triggers, and desensitization to these triggers can be helpful in some physical Urticarias and in cholinergic Urticaria.
-
anti immunoglobulin e treatment of patients with recalcitrant physical Urticaria
International Archives of Allergy and Immunology, 2011Co-Authors: Martin Metz, Erika Ardelean, Frank Siebenhaar, K. Weller, Birgit Kessler, Karoline Krause, Sabine Altrichter, Markus Magerl, Torsten ZuberbierAbstract:In physical Urticaria, exogenous physical factors such as thermal triggers, solar radiation and mechanic triggers including friction or pressure are responsible for the elicitation of symptoms in the skin of patients. Avoidance of the respective stimulus is usually difficult or impossible, and many patients are not sufficiently treated with standard antihistamines. We report that treatment with omalizumab (Xolair®) of 7 patients with physical Urticarias [solar Urticaria (n = 2), Urticaria factitia/symptomatic dermographism (n = 2), cold Urticaria, delayed pressure Urticaria and localized heat Urticaria] resulted in complete symptom control within days after the first injection in 5 patients. In 1 patient, symptoms improved after increasing the dose of omalizumab, and 1 patient with localized heat Urticaria did not respond significantly to treatment. Before anti-immunoglobulin E treatment, all patients had suffered from their physical Urticaria for years and had had numerous unsuccessful therapies. The overall excellent responses to omalizumab treatment reported here indicate that anti-immunoglobulin E is a safe and effective treatment for recalcitrant physical Urticarias.
-
Urticaria current opinions about etiology diagnosis and therapy
Acta Dermato-venereologica, 2007Co-Authors: Torsten Zuberbier, Marcus MaurerAbstract:In the last few decades an increasing understanding of the pathomechanisms involved in Urticaria has highlighted the heterogeneity of different subtypes. According to the new European Academy of Allergology and Clinical Immunology/Global Allergy and Asthma European Network/European Dermatology Forum (EAACI/GA(2)LEN/ EDF) guidelines, Urticaria subtypes can be grouped into spontaneous Urticaria, which includes acute Urticaria and chronic Urticaria, the physical Urticarias, and other Urticaria disorders, including, for example, contact Urticaria. Clarity of nomenclature is required not only to choose the correct measures in diagnosis and management, but also to compare data from different studies. Urticaria has a profound impact on quality of life and performance. Effective treatment is thus required in all cases where avoidance of eliciting factors is not feasible. For symptomatic relief, non-sedating H1-antihistamines are the first choice in most subtypes of Urticaria; however, double-blind controlled studies have shown that the dosages required may exceed those recommended for other diseases, e.g. allergic rhinitis. The current guidelines therefore suggest increasing the dosage up to four-fold, whereas alternative treatments should be reserved as add-on therapy for unresponsive patients.
Markus Magerl - One of the best experts on this subject based on the ideXlab platform.
-
the definition diagnostic testing and management of chronic inducible Urticarias the eaaci ga2len edf unev consensus recommendations 2016 update and revision
Allergy, 2016Co-Authors: Markus Magerl, Sabine Altrichter, Torsten Zuberbier, Elena Borzova, A Gimenezarnau, Clive Grattan, F Lawlor, P Mathelierfusade, Raisa Meshkova, Martin MetzAbstract:These recommendations for the definition, diagnosis and management of chronic inducible Urticaria (CIndU) extend, revise and update our previous consensus report on physical Urticarias and cholinergic Urticaria (Allergy, 2009). The aim of these recommendations is to improve the diagnosis and management of patients with CIndU. Our recommendations acknowledge the latest changes in our understanding of CIndU, and the available therapeutic options, as well as the development of novel diagnostic tools.
-
anti immunoglobulin e treatment of patients with recalcitrant physical Urticaria
International Archives of Allergy and Immunology, 2011Co-Authors: Martin Metz, Erika Ardelean, Frank Siebenhaar, K. Weller, Birgit Kessler, Karoline Krause, Sabine Altrichter, Markus Magerl, Torsten ZuberbierAbstract:In physical Urticaria, exogenous physical factors such as thermal triggers, solar radiation and mechanic triggers including friction or pressure are responsible for the elicitation of symptoms in the skin of patients. Avoidance of the respective stimulus is usually difficult or impossible, and many patients are not sufficiently treated with standard antihistamines. We report that treatment with omalizumab (Xolair®) of 7 patients with physical Urticarias [solar Urticaria (n = 2), Urticaria factitia/symptomatic dermographism (n = 2), cold Urticaria, delayed pressure Urticaria and localized heat Urticaria] resulted in complete symptom control within days after the first injection in 5 patients. In 1 patient, symptoms improved after increasing the dose of omalizumab, and 1 patient with localized heat Urticaria did not respond significantly to treatment. Before anti-immunoglobulin E treatment, all patients had suffered from their physical Urticaria for years and had had numerous unsuccessful therapies. The overall excellent responses to omalizumab treatment reported here indicate that anti-immunoglobulin E is a safe and effective treatment for recalcitrant physical Urticarias.
-
the definition and diagnostic testing of physical and cholinergic Urticarias eaaci ga2len edf unev consensus panel recommendations
Allergy, 2009Co-Authors: Markus Magerl, Martin Metz, Elena Borzova, A Gimenezarnau, F Lawlor, P Mathelierfusade, C E H Grattan, A Mlynek, Marcus MaurerAbstract:The recommendations for the definition and diagnosis presented in this position paper are the result of a panel consensus meeting held in December 2008 in Berlin. This consensus meeting was a joint initiative of EAACI (European Academy of Allergology and Clinical Immunology) Dermatology Section, the EU-funded network of excellence, GA2LEN (Global Allergy and Asthma European Network), the EDF (European Dermatology Forum) and UNEV (Urticaria network e.V.). The aim of these recommendations is to improve the diagnosis and management of patients with physical Urticaria or cholinergic Urticaria and to promote research and a better understanding of these diseases. Our recommendations used the paper produced by a 1996 expert meeting (1) and they acknowledge the latest changes in our understanding of physical Urticarias and cholinergic Urticaria as well as the recent development of novel diagnostic tools. In addition, this consensus paper highlights areas of need for further research.
Sabine Altrichter - One of the best experts on this subject based on the ideXlab platform.
-
benefit from reslizumab treatment in a patient with chronic spontaneous Urticaria and cold Urticaria
Journal of The European Academy of Dermatology and Venereology, 2018Co-Authors: Marcus Maurer, Sabine Altrichter, Martin Metz, Torsten Zuberbier, Martin K Church, Karl Christian BergmannAbstract:Chronic Urticaria (CU) is a group of common and debilitating conditions containing both chronic spontaneous Urticaria (CSU) and chronic inducible Urticarias (CIndU) including cold Urticaria (ColdU) [1]. While antihistamines and omalizumab are effective treatments for both CSU and ColdU [2], many patients show insufficient response to either or both of these treatments [3], and additional and better therapies are needed [4]. This article is protected by copyright. All rights reserved.
-
the definition diagnostic testing and management of chronic inducible Urticarias the eaaci ga2len edf unev consensus recommendations 2016 update and revision
Allergy, 2016Co-Authors: Markus Magerl, Sabine Altrichter, Torsten Zuberbier, Elena Borzova, A Gimenezarnau, Clive Grattan, F Lawlor, P Mathelierfusade, Raisa Meshkova, Martin MetzAbstract:These recommendations for the definition, diagnosis and management of chronic inducible Urticaria (CIndU) extend, revise and update our previous consensus report on physical Urticarias and cholinergic Urticaria (Allergy, 2009). The aim of these recommendations is to improve the diagnosis and management of patients with CIndU. Our recommendations acknowledge the latest changes in our understanding of CIndU, and the available therapeutic options, as well as the development of novel diagnostic tools.
-
physical Urticarias and cholinergic Urticaria
Immunology and Allergy Clinics of North America, 2014Co-Authors: Marina Abajian, Sabine Altrichter, N Schoepke, Torsten ZuberbierAbstract:: Physical Urticarias are a unique subgroup of chronic Urticaria in which Urticarial responses can be reproducibly induced by different specific physical stimuli acting on the skin. These conditions include Urticaria factitia/symptomatic dermographism, delayed pressure Urticaria, cold contact Urticaria, heat contact Urticaria, solar Urticaria, and vibratory Urticaria/angioedema. Physical Urticarias and cholinergic Urticarias are diagnosed based on the patients' history and provocation tests including trigger threshold testing where possible. Treatment is mainly symptomatic. Many patients benefit from avoiding eliciting triggers, and desensitization to these triggers can be helpful in some physical Urticarias and in cholinergic Urticaria.
-
anti immunoglobulin e treatment of patients with recalcitrant physical Urticaria
International Archives of Allergy and Immunology, 2011Co-Authors: Martin Metz, Erika Ardelean, Frank Siebenhaar, K. Weller, Birgit Kessler, Karoline Krause, Sabine Altrichter, Markus Magerl, Torsten ZuberbierAbstract:In physical Urticaria, exogenous physical factors such as thermal triggers, solar radiation and mechanic triggers including friction or pressure are responsible for the elicitation of symptoms in the skin of patients. Avoidance of the respective stimulus is usually difficult or impossible, and many patients are not sufficiently treated with standard antihistamines. We report that treatment with omalizumab (Xolair®) of 7 patients with physical Urticarias [solar Urticaria (n = 2), Urticaria factitia/symptomatic dermographism (n = 2), cold Urticaria, delayed pressure Urticaria and localized heat Urticaria] resulted in complete symptom control within days after the first injection in 5 patients. In 1 patient, symptoms improved after increasing the dose of omalizumab, and 1 patient with localized heat Urticaria did not respond significantly to treatment. Before anti-immunoglobulin E treatment, all patients had suffered from their physical Urticaria for years and had had numerous unsuccessful therapies. The overall excellent responses to omalizumab treatment reported here indicate that anti-immunoglobulin E is a safe and effective treatment for recalcitrant physical Urticarias.
